Trial · NCT01431339
Adverse events66
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 66
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Dalbavancin | 15 | 368 | |
| other | Nausea | Gastrointestinal disorders | Vancomycin With Possible Switch to Oral Linezolid | 15 | 367 | |
| other | Headache | Nervous system disorders | Dalbavancin | 11 | 368 | |
| other | Headache | Nervous system disorders | Vancomycin With Possible Switch to Oral Linezolid | 9 | 367 | |
| other | Vomiting | Gastrointestinal disorders | Dalbavancin | 8 | 368 | |
| other | Vomiting | Gastrointestinal disorders | Vancomycin With Possible Switch to Oral Linezolid | 4 | 367 | |
| other | Diarrhoea | Gastrointestinal disorders | Dalbavancin | 4 | 368 | |
| other | Diarrhoea | Gastrointestinal disorders | Vancomycin With Possible Switch to Oral Linezolid | 8 | 367 | |
| serious | Systemic inflammatory response syndrome | General disorders | Dalbavancin | 0 | 368 | |
| serious | Systemic inflammatory response syndrome | General disorders | Vancomycin With Possible Switch to Oral Linezolid | 1 | 367 | |
| serious | Erythema | Skin and subcutaneous tissue disorders | Dalbavancin | 0 | 368 | |
| serious | Erythema | Skin and subcutaneous tissue disorders | Vancomycin With Possible Switch to Oral Linezolid | 1 | 367 | |
| serious | Inguinal hernia | Gastrointestinal disorders | Dalbavancin | 1 | 368 | |
| serious | Inguinal hernia | Gastrointestinal disorders | Vancomycin With Possible Switch to Oral Linezolid | 0 | 367 | |
| serious | Blood glucose increased | Investigations | Dalbavancin | 0 | 368 | |
| serious | Blood glucose increased | Investigations | Vancomycin With Possible Switch to Oral Linezolid | 1 | 367 | |
| serious | Cardiac failure congestive | Cardiac disorders | Dalbavancin | 1 | 368 | |
| serious | Cardiac failure congestive | Cardiac disorders | Vancomycin With Possible Switch to Oral Linezolid | 0 | 367 | |
| serious | Abscess | Infections and infestations | Dalbavancin | 0 | 368 | |
| serious | Abscess | Infections and infestations | Vancomycin With Possible Switch to Oral Linezolid | 1 | 367 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01431339/events